Contrasting Pulse Biosciences (NASDAQ:PLSE) & Co-Diagnostics (NASDAQ:CODX)

Share on StockTwits

Pulse Biosciences (NASDAQ:PLSE) and Co-Diagnostics (NASDAQ:CODX) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, valuation, earnings, profitability, analyst recommendations, dividends and risk.

Profitability

This table compares Pulse Biosciences and Co-Diagnostics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Pulse Biosciences N/A -82.64% -75.52%
Co-Diagnostics -19,057.66% -430.95% -204.92%

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Pulse Biosciences and Co-Diagnostics, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Pulse Biosciences 0 0 1 0 3.00
Co-Diagnostics 0 0 2 0 3.00

Pulse Biosciences presently has a consensus target price of $27.00, suggesting a potential upside of 114.29%. Co-Diagnostics has a consensus target price of $2.00, suggesting a potential upside of 124.72%. Given Co-Diagnostics’ higher probable upside, analysts clearly believe Co-Diagnostics is more favorable than Pulse Biosciences.

Insider & Institutional Ownership

9.1% of Pulse Biosciences shares are held by institutional investors. Comparatively, 10.6% of Co-Diagnostics shares are held by institutional investors. 48.6% of Pulse Biosciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Earnings and Valuation

This table compares Pulse Biosciences and Co-Diagnostics’ top-line revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Pulse Biosciences N/A N/A -$37.54 million ($2.20) -5.73
Co-Diagnostics $40,000.00 378.58 -$6.27 million N/A N/A

Co-Diagnostics has higher revenue and earnings than Pulse Biosciences.

Summary

Co-Diagnostics beats Pulse Biosciences on 5 of the 9 factors compared between the two stocks.

About Pulse Biosciences

Pulse Biosciences, Inc. operates as a clinical stage medical therapy company. It engages in the research and development, and commercialization of CellFX system that provides a precise and non-thermal cellular treatment technology delivering nanosecond duration energy pulses that impact cells in treated tissue while sparing surrounding non-cellular tissue primarily for dermatology applications. The company was formerly known as Electroblate, Inc. and changed its name to Pulse Biosciences, Inc. in December 2015. Pulse Biosciences, Inc. was founded in 2014 and is headquartered in Hayward, California.

About Co-Diagnostics

Co-Diagnostics, Inc., a molecular diagnostics company, intends to manufacture and sell reagents used for diagnostic tests that function via the detection and/or analysis of nucleic acid molecules. It also intends to sell diagnostic equipment from other manufacturers as self-contained lab systems. Co-Diagnostics, Inc. was founded in 2013 and is headquartered in Salt Lake City, Utah.

Receive News & Ratings for Pulse Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pulse Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

HollyWoodCoin  Price Hits $0.0015 on Exchanges
HollyWoodCoin Price Hits $0.0015 on Exchanges
Sprouts  Price Hits $0.0000 on Exchanges
Sprouts Price Hits $0.0000 on Exchanges
AMLT Token  Trading Down 2.2% Over Last 7 Days
AMLT Token Trading Down 2.2% Over Last 7 Days
JFS Wealth Advisors LLC Takes $133,000 Position in iShares 20+ Year Treasury Bond ETF
JFS Wealth Advisors LLC Takes $133,000 Position in iShares 20+ Year Treasury Bond ETF
JFS Wealth Advisors LLC Has $440,000 Stake in iShares Russell 2000 Value ETF
JFS Wealth Advisors LLC Has $440,000 Stake in iShares Russell 2000 Value ETF
Tealwood Asset Management Inc. Has $3.84 Million Stock Holdings in Edison International
Tealwood Asset Management Inc. Has $3.84 Million Stock Holdings in Edison International


 
© 2006-2019 Zolmax.